BLT
02/02/2015 08:30
GENERAL
PRICE SENSITIVE
REL: 0830 HRS BLIS Technologies Limited
GENERAL: BLT: New study- Effectiveness of BLIS M18 probiotic
Price sensitive announcement
New study demonstrates effectiveness of BLIS M18TM probiotic
February 1, 2015
BLIS Technologies Ltd, Dunedin (BLT)
BLT this week received advice of the publication of results of a new
independent clinical trial of BLIS M18, a novel probiotic for the support of
oral and periodontal health. The Indian clinical trial involved 28 adult
volunteers with moderate to severe periodontitis. The results demonstrated
that the sub-group of participants taking the probiotic BLIS M18 lozenges for
one month recorded statistically significant improvements in multiple indices
of periodontal health. The research has recently been published in the
International Journal of Pharma and Bio Science.
In commenting, the Chief Executive of BLIS Technologies, Dr Barry Richardson,
noted that this independent study provided further evidence of the
effectiveness of BLIS M18 in improving periodontal health. The study authors
summarized their findings by stating that "Streptococcus salivarius M18 may
be potentially useful as an aid in improving the oral health of periodontal
patients".
BLIS M18 is a member of the bacterial species Streptococcus salivarius
originally developed by BLIS Technologies Ltd in Dunedin, New Zealand for the
support of oral health. One aspect of the probiotic's mechanism of action is
the production of multiple bacteriocins (naturally produced substances) that
selectively inhibit the growth of oral pathogens involved in the development
of dental caries including Streptococcus mutans.
Reference: Scariya, L et al (2015). Int J Pharm Bio Sci 6(1): 242 - 250
BLIS Technologies Ltd supplied the BLIS M18 lozenges used by the researchers
in this study.
For further comment contact:
Barry Richardson 021 664 742
End CA:00260190 For:BLT Type:GENERAL Time:2015-02-02 08:30:07
